Anika Therapeutics Second Quarter 2025 Earnings: Beats Expectations

Anika Therapeutics (NASDAQ:ANIK) Second Quarter 2025 Results

Key Financial Results

• Revenue: US$28.2m (down 8.2% from 2Q 2024).
• Net loss: US$4.65m (loss widened by 83% from 2Q 2024).
• US$0.32 loss per share (further deteriorated from US$0.17 loss in 2Q 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Anika Therapeutics Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 4.4%. Earnings per share (EPS) also surpassed analyst estimates by 11%.

Looking ahead, revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 24% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 1 warning sign for Anika Therapeutics that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.